Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

You might know Sydney Jo, aka @ thatgirlsydjo, for her TikTok project, The Group Chat, which she wrote on her Notes app ...

Small-group instruction has been a popular component of K-3 literacy education for many years. However, there are inevitable ...

When a therapist used AI without consent, trust was broken. Here’s what clients deserve to know—and what ethical AI use in ...

When culture shapes how clients express emotion, therapists may misread the moment. Here’s how to see what’s really happening ...

The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy results for CUTX-101, demonstrating significant improvement in overall survival ...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...

Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...

Arovella Therapeutics Limited ( ($AU:ALA) ) has shared an announcement. Arovella Therapeutics Limited has issued 371,187 ordinary shares without ...

Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses([1]) , while ...

– Oral and poster presentations to include seizure and neurodevelopmental data from POLARIS Phase 1/2 Program that support advancement of ETX101 – SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

As wellness and aesthetics merge, light therapy technology has shifted from industry niche to everyday essential—and Omnilux has been quietly leading the charge. “The surge in demand comes down to ...